Avadel Pharmaceuticals plc(NASDAQ:AVDL) 
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company's lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. T...
Website: http://www.avadel.com
Founded: 1990
Full Time Employees: 50
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 7.00
H 7.07
L 6.60
C 6.80
V 1,169,986
10EMA 6.80
20EMA 6.80
60EMA 6.80
120EMA 6.80
250EMA 6.80